<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        95-68-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TWYNSTA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TELMISARTAN,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        72.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Cipla Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Cipla Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Twynsta tablets contain two active substances called telmisartan and amlodipine. Both of these substances help to control your high blood pressure:&nbsp;</p><ul><li><p>Telmisartan belongs to a group of substances called &ldquo;angiotensin-II receptor blockers&rdquo;. Angiotensin II is a substance produced in the body, which causes blood vessels to narrow, thus increasing blood pressure. Telmisartan works by blocking the effect of angiotensin II.&nbsp;</p></li></ul><ul><li><p>Amlodipine belongs to a group of substances called &ldquo;calcium channel blockers&rdquo;. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening.&nbsp;</p></li></ul><p>This means that both of these active substances work together to help stop your blood vessels tightening.&nbsp;</p><p>As a result, the blood vessels relax and blood pressure is lowered.&nbsp;</p><p>&nbsp;</p><p>Twynsta is used to treat high blood pressure&nbsp;</p><ul><li><p>in adult patients whose blood pressure is not controlled enough with amlodipine alone.&nbsp;</p></li></ul><ul><li><p>in adult patients who already receive telmisartan and amlodipine from separate tablets and who wish to take instead the same doses in one tablet for convenience.&nbsp;</p></li></ul><p>&nbsp;</p><p>High blood pressure, if not treated, can damage blood vessels in several organs, which puts patients at risk of serious events such as heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus, it is important to regularly measure blood pressure to verify if it is within the normal range.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>TWYNSTA</strong></p><ul><li><p>if you are allergic to telmisartan or amlodipine or any of the other ingredients of this medicine (listed in section 6).&nbsp;</p></li></ul><ul><li><p>if you are allergic to other medicines of the dihydropyridine type (one type of calcium channel blocker).&nbsp;</p></li></ul><ul><li><p>if you are more than 3 months pregnant. (It is also better to avoid Twynsta in early pregnancy &ndash; see Pregnancy section.)&nbsp;</p></li></ul><ul><li><p>if you have severe liver problems or biliary obstruction (problems with drainage of the bile from the liver and gall bladder).&nbsp;</p></li></ul><ul><li><p>if you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).&nbsp;&nbsp;</p></li></ul><ul><li><p>if you suffer from heart failure after a heart attack.&nbsp;</p></li></ul><ul><li><p>if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.&nbsp;</p></li></ul><p>If any of the above applies to you, tell your doctor or pharmacist before taking Twynsta.&nbsp;</p><p>Warnings and precautions&nbsp;</p><p>Talk to your doctor before taking Twynsta if you are suffering or have ever suffered from any of the following conditions or illnesses:&nbsp;</p><ul><li><p>Kidney disease or kidney transplant.&nbsp;</p></li></ul><ul><li><p>Narrowing of the blood vessels to one or both kidneys (renal artery stenosis).&nbsp;</p></li></ul><ul><li><p>Liver disease.&nbsp;</p></li></ul><ul><li><p>Heart trouble.&nbsp;</p></li></ul><ul><li><p>Raised aldosterone levels (which lead to water and salt retention in the body along with imbalance of various blood minerals).&nbsp;</p></li></ul><ul><li><p>Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy (&lsquo;water tablets&rsquo;), low-salt diet, diarrhoea, or vomiting.&nbsp;</p></li></ul><ul><li><p>Elevated potassium levels in your blood.&nbsp;</p></li></ul><ul><li><p>Diabetes.&nbsp;</p></li></ul><ul><li><p>Narrowing of the aorta (aortic stenosis).&nbsp;</p></li></ul><ul><li><p>Heart-associated chest pain also at rest or with minimal effort (unstable angina pectoris).&nbsp;</p></li></ul><ul><li><p>A heart attack within the last four weeks.&nbsp;</p></li></ul><p>Talk to your doctor before taking Twynsta:&nbsp;</p><ul><li><p>if you are taking any of the following medicines used to treat high blood pressure:&nbsp;</p></li></ul><p>- an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes- related kidney problems.&nbsp;</p><p>- aliskiren.&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also &ldquo;Do not take Twynsta&rdquo;.&nbsp;</p><ul><li><p>if you are elderly and your dose needs to be increased.&nbsp;</p></li></ul><p>&nbsp;</p><p>Talk to your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking Twynsta. Your doctor will decide on further treatment. Do not stop taking Twynsta on your own.&nbsp;</p><p>&nbsp;</p><p>In case of surgery or anaesthesia, you should tell your doctor that you are taking Twynsta.&nbsp;</p><p>&nbsp;</p><p>Children and adolescents&nbsp;</p><p>Twynsta is not recommended in children and adolescents up to the age of 18 years.&nbsp;</p><p>Other medicines and Twynsta&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.&nbsp;</p><p>Your doctor may need to change the dose of these other medicines or take other precautions. In some cases, you may have to stop taking one of the medicines. This applies especially to the medicines listed below:&nbsp;</p><ul><li><p>Lithium-containing medicines to treat some types of depression.&nbsp;</p></li></ul><ul><li><p>Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain &lsquo;water tablets&rsquo;).&nbsp;</p></li></ul><ul><li><p>Angiotensin II receptor blockers.&nbsp;</p></li></ul><ul><li><p>ACE-inhibitors or aliskiren (see also information under the headings &ldquo;Do not take Twynsta&rdquo; and &ldquo;Warnings and precautions&rdquo;).&nbsp;</p></li></ul><ul><li><p>NSAIDs (non steroidal anti-inflammatory medicines, e.g. acetylsalicylic acid or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.&nbsp;</p></li></ul><ul><li><p>Rifampicin, erythromycin, clarithromycin (antibiotics)&nbsp;</p></li></ul><ul><li><p>St. John&rsquo;s wort.&nbsp;</p></li></ul><ul><li><p>Dantrolene (infusion for severe body temperature abnormalities).&nbsp;</p></li></ul><ul><li><p>Medicines used to alter the way your immune system works (e.g. sirolimus, temsirolimus and everolimus).&nbsp;</p></li></ul><ul><li><p>Medicines used for HIV/AIDS (e.g. ritonavir) or for treatment of fungal infections (e.g.ketoconazole).&nbsp;</p></li></ul><ul><li><p>Diltiazem (cardiac medicine).&nbsp;</p></li></ul><ul><li><p>Simvastatin to treat elevated levels of cholesterol.&nbsp;</p></li></ul><ul><li><p>Digoxin.&nbsp;</p></li></ul><p>As with other blood pressure lowering medicines, the effect of Twynsta may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. acetylsalicylic acid or ibuprofen) or corticosteroids.&nbsp;</p><p>Twynsta may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine, neuroleptics or antidepressants).&nbsp;</p><p>Twynsta with food and drink&nbsp;</p><p>Low blood pressure may be aggravated by alcohol. You may notice this as dizziness when standing up.&nbsp;</p><p>&nbsp;</p><p>Grapefruit juice and grapefruit should not be consumed when you take Twynsta. This is because grapefruit and grapefruit juice may lead to increased blood levels of the active ingredient amlodipine in some patients and may increase the blood pressure lowering effect of Twynsta.&nbsp;</p><p>&nbsp;</p><p>Pregnancy and breast-feeding&nbsp;</p><p>Pregnancy&nbsp;</p><p>You must tell your doctor if you think you might be pregnant or are planning to have a baby. Your doctor will normally advise you to stop taking Twynsta before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Twynsta. Twynsta is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.&nbsp;</p><p>&nbsp;</p><p>Breast-feeding&nbsp;</p><p>Amlodipine has been shown to pass into breast milk in small amounts.&nbsp;</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Twynsta is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.&nbsp;</p><p>&nbsp;</p><p>Driving and using machines&nbsp;</p><p>Some people may experience side effects such as fainting, sleepiness, dizziness or a feeling of spinning (vertigo) when they are treated for high blood pressure. If you experience these side effects, do not drive or use machines.&nbsp;</p><p>&nbsp;</p><p>Twynsta contains sorbitol&nbsp;</p><p>This medicine contains 337.28 mg sorbitol in each tablet.&nbsp;</p><p>&nbsp;</p><p>Sorbitol is a source of fructose. If your doctor has told you that, you have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you take or receive this medicine.&nbsp;</p><p>&nbsp;</p><p>Twynsta contains sodium&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.&nbsp;</p><p>The recommended dose is one tablet a day. Try to take the tablet at the same time each day.&nbsp;</p><p>Remove your Twynsta tablet from the blister only directly prior to intake.&nbsp;</p><p>&nbsp;</p><p>You can take Twynsta with or without food. The tablets should be swallowed with some water or other non-alcoholic drink.&nbsp;</p><p>If your liver is not working properly, the usual dose should not exceed one 40 mg/5 mg tablet or one 40 mg/10 mg tablet per day.&nbsp;</p><p>If you take more Twynsta than you should&nbsp;</p><p>If you accidentally take too many tablets, contact your doctor, pharmacist, or your nearest hospital emergency department immediately. You might experience low blood pressure and rapid heart beat. Slow heart beat, dizziness, reduced kidney function including kidney failure, marked and prolonged low blood pressure including shock and death have also been reported.&nbsp;</p><p>&nbsp;</p><p>Excess fluid may accumulate in your lungs (pulmonary oedema) causing shortness of breath that may develop up to 24-48 hours after intake.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>If you forget to take Twynsta&nbsp;</p><p>If you forget to take a dose, take it as soon as you remember and then carry on as before. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for forgotten individual doses.&nbsp;</p><p>&nbsp;</p><p>If you stop taking Twynsta&nbsp;</p><p>It is important that you take Twynsta every day until your doctor tells you otherwise. If you have the impression that the effect of Twynsta is too strong or too weak, talk to your doctor or pharmacist.&nbsp;</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p>Some side effects can be serious and need immediate medical attention:&nbsp;</p><p>You should see your doctor immediately if you experience any of the following symptoms:&nbsp;</p><p>Sepsis (often called &quot;blood poisoning&quot;, is a severe infection of the whole-body with high fever and the feeling of being severely ill), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. If these effects are not treated, they could be fatal. Increased incidence of sepsis has been observed with telmisartan only, however can not be ruled out for Twynsta.&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people)&nbsp;&nbsp;</p><p>Dizziness, ankle swelling (oedema).&nbsp;</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people)&nbsp;</p><p>Sleepiness, migraine, headache, tingling or numbness of the hands or feet, feeling of spinning (vertigo), slow heart rate, palpitations (awareness of your heart beat), low blood pressure (hypotension), dizziness on standing up (orthostatic hypotension), flushing, cough, stomach ache (abdominal pain), diarrhoea, feeling sick (nausea), itching, joint pain, muscle cramps, muscle pain, inability to obtain an erection, weakness, chest pain, tiredness, swelling (oedema), increased levels of hepatic enzymes.&nbsp;</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people)&nbsp;</p><p>Urinary bladder infection, feeling sad (depression), feeling anxious, sleeplessness, fainting, nerve damage in the hands or feet, reduced sense of touch, taste abnormalities, trembling, vomiting, enlarged gums, discomfort in the abdomen, dry mouth, eczema (a skin disorder), redness of skin, rash, back pain, leg pain, urge to urinate during the night, feeling unwell (malaise), increased levels of uric acid in the blood.&nbsp;</p><p>&nbsp;</p><p>Very rare side effect (may affect up to 1 in 10,000 people)&nbsp;</p><p>Progressive scarring of lung tissue (interstitial lung disease [mainly pneumonia of the interstitium and pneumonia with excess eosinophils])&nbsp;</p><p>&nbsp;</p><p>The following side effects have been observed with the components telmisartan or amlodipine and may occur also with Twynsta:&nbsp;</p><p>&nbsp;</p><p>Telmisartan&nbsp;</p><p>In patients taking telmisartan alone the following additional side effects have been reported:&nbsp;</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people)&nbsp;</p><p>Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels in the blood, shortness of breath, bloating, increased sweating, kidney damage including sudden inability of the kidneys to work, increased levels of creatinine.&nbsp;</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people)&nbsp;</p><p>Increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), allergic reaction (e.g. rash, itching, difficulty of breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), impaired vision, fast heart beat, upset stomach, abnormal liver function, hives (urticaria), medicine rash, inflammation of the tendons, flu-like illness (for example muscle pain, feeling generally unwell), decreased haemoglobin (a blood protein), increased levels of creatinine phosphokinase in the blood, low levels of sodium.&nbsp;</p><p>&nbsp;</p><p>Most cases of abnormal liver function and liver disorder from post-marketing experience with telmisartan occurred in Japanese patients. Japanese patients are more likely to experience this side effect.&nbsp;</p><p>&nbsp;</p><p>Not known&nbsp;&nbsp;</p><p>Intestinal angioedema: a swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting, and diarrhoea has been reported after the use of similar products.&nbsp;</p><p>&nbsp;</p><p>Amlodipine&nbsp;</p><p>In patients taking amlodipine alone the following additional side effects have been reported:&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people)&nbsp;</p><p>Altered bowel habits, diarrhoea, constipation, visual disturbances, double vision, ankle swelling.&nbsp;</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people)&nbsp;</p><p>Mood changes, impaired vision, ringing in the ears, shortness of breath, sneezing/running nose, hair loss, unusual bruising and bleeding (red blood cell damage), skin discoloration, increased sweating, difficulty passing urine, increased need to pass urine especially at night, enlarging of male breasts, pain, weight increased, weight decreased.&nbsp;</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people)&nbsp;</p><p>Confusion.&nbsp;</p><p>&nbsp;</p><p>Very rare side effects (may affect up to 1 in 10,000 people)&nbsp;</p><p>Reduced number of white blood cells (leucopenia), low platelet count (thrombocytopenia), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), excess sugar in blood , uncontrollable twitching or jerking movements, heart attack, irregular heartbeat, inflammation of the blood vessels, inflamed pancreas, inflammation of the stomach lining (gastritis), inflammation of the liver, yellowing of the skin (jaundice), increased levels of hepatic enzymes with jaundice, rapid swelling of skin and mucosa (angioedema), severe skin reactions, hives (urticaria), severe allergic reactions with blistering eruptions of the skin and mucous membranes (exfoliative dermatitis, Stevens-Johnson-Syndrome), increased sensitivity of the skin to sun, increased muscle tension.&nbsp;</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)&nbsp;</p><p>Severe allergic reactions with blistering eruptions of the skin and mucous membranes (toxic epidermal necrolysis).&nbsp;</p><p>&nbsp;</p><p>Reporting of side effects&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.&nbsp;&nbsp;</p><p>By reporting side effects you can help provide more information on the safety of this medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the carton, and blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.&nbsp;</p><p>Store below 30&deg;C.&nbsp; Store in the original package in order to protect from light and moisture. Remove your Twynsta tablet from the blister only directly prior to intake.&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substances are telmisartan and amlodipine.&nbsp;</p><p>Twynsta 80/5 mg: Each tablet contains 80 mg telmisartan and 5 mg amlodipine (as amlodipine besylate).&nbsp;</p><p>Twynsta 80/10 mg: Each tablet contains 80 mg telmisartan and 10 mg amlodipine (as amlodipine besylate).&nbsp;</p><p>- The other ingredients are colloidal anhydrous silica, brilliant blue FCF (E133), ferric oxide black (E172), ferric oxide yellow (E172), magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone K25, pregelatinized starch prepared from maize starch, sodium hydroxide&nbsp; (see section 2), sorbitol (E420) (see section 2).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Twynsta 80 mg/5 mg tablets are blue and white oval shaped two layer tablets of approximately 16 mm length engraved with the product code A3 and the company logo on the white layer. 

Twynsta 80 mg/10 mg tablets are blue and white oval shaped two layer tablets of approximately 16 mm length engraved with the product code A4 and the company logo on the white layer. 

Twynsta is available in a folding box containing 14 (7x2), 28 (7x4), 56(7x8), 98 (7x14) tablets in aluminium/aluminium blisters or containing 30, 90, 360 (4 x 90) tablets in aluminium/aluminium perforated unit dose blisters. 

Not all strengths and pack sizes are registered or marketed in your country. 

 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Boehringer Ingelheim International GmbH</p><p>Binger Strasse 173</p><p>55216 Ingelheim am Rhein</p><p>Germany</p><p><strong>&nbsp;</strong></p><p><strong>Bulk Manufacturer</strong></p><p>Cipla Ltd.</p><p>Plot No.L-139 to L-146,</p><p>Verna Industrial Estate,</p><p>Verna-Goa</p><p>India</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي تونيستا أقراص على مادتين فعَّالتين تُسميَّان تلميسارتان وأملوديبين. تُساعِد كلتا المادتين على التحكم في ضغط الدَّم المرتفع لديك:&nbsp;</p><ul><li><p>ينتمي تلميسارتان إلى مجموعة من المواد تُسمى: &quot;حاصرات مستقبلات الأنجيوتنسين -2&quot;. أنجيوتنسين-2 هو عبارة عن مادة تنتج داخل الجسم وتسبب تضيُّق الأوعية الدموية ، وبالتالي ارتفاع ضغط الدَّم. يعمل تلميسارتان عن طريق منع تأثير أنجيوتنسين-2.&nbsp;</p></li></ul><ul><li><p>ينتمي أملوديبين إلى مجموعة من المواد تُسمى: &quot;حاصرات قنوات الكالسيوم&quot;. يمنع أملوديبين الكالسيوم من الانتقال إلى جدار الأوعية الدَّموية الأمر الذي يوقف تضيُّق الأوعية الدَّموية.&nbsp;</p></li></ul><p>هذا يعني أن كل مادة من هاتين المادتين تعمل مع الأخرى للمساعدة على وقف تضيُّق الأوعية الدَّموية.&nbsp;&nbsp;</p><p>نتيجة لذلك، ترتخي الأوعية الدَّموية وينخفض ضغط الدَّم.&nbsp;</p><p>&nbsp;</p><p>يُستخدم تونيستا لعلاج ارتفاع ضغط الدَّم&nbsp;</p><ul><li><p>في المرضى البالغين ممن لا يُمكِن التحكُّم في ضغط الدَّم لديهم بشكل كافٍ بـأملوديبين بمفرده.&nbsp;</p></li></ul><ul><li><p>في المرضى البالغين ممن يتلقون بالفعل تلميسارتان وأملوديبين كأقراص منفصلة والذين يرغبون في تناوُل الجرعات نفسها في قرص واحد لتوفير الرَّاحة.&nbsp;</p></li></ul><p>&nbsp;</p><p>إذا لم يتم علاج ارتفاع ضغط الدَّم، يمكن أن يؤدي إلى تلف الأوعية الدَّموية في عدة أعضاء بالجسم، الأمر الذي قد يعرض المرضى لخطر حدوث اعراض خطيرة مثل نوبة قلبية، فشل القلب أو الكلى، السكتة الدماغية، أو فقدان البصر. عادةً لا تكون هناك أعراض لارتفاع ضغط الدَّم قبل حدوث التَّلف. وبالتالي فإنه من المهم قياس ضغط الدَّم بانتظام للتحقق مما إذا كان في النطاق الطبيعي أم لا.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول تونيستا في الحالات الآتية</strong></p><p>&nbsp;</p><ul><li><p>إذا كنت تعاني من حساسية تجاه تلميسارتان أو أملوديبين أو أيٍّ من المكونات الأخرى بهذا الدواء (المدرجة في قسم 6).&nbsp;</p></li></ul><ul><li><p>إذا كنت تُعاني من حساسية تجاه الأدوية الأخرى من نوع الديهيدروبيريدين (أحد أنواع حاصرات قنوات الكالسيوم).&nbsp;</p></li></ul><ul><li><p>إذا كنتِ حاملًا لأكثر من 3 أشهر. (من الأفضل أيضًا تجنُّب تناوُل تونيستا في مراحل الحمل المبكرة - انظري قسم الحمل(.&nbsp;</p></li></ul><ul><li><p>إذا كان لديك مشاكل شديدة بالكبد أو انسداد صفراوي (مشاكل في تصريف العصارة الصفراوية من الكبد والمرارة).&nbsp;</p></li></ul><ul><li><p>&nbsp; إذا كنت مُصابًا بتضيُّق في الصمام الأورطي أو صدمة قلبية (حالة يكون فيها قلبك غير قادر على إمداد الجسم&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بكمية كافية من الدَّم).&nbsp;</p></li></ul><ul><li><p>إذا كنت تعاني من فشل القلب بعد التعرُّض لنوبة قلبية .&nbsp;</p></li></ul><ul><li><p>إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور في وظائف الكُلى، ويتم علاجك بدواء خافض لضغط الدَّم يحتوي على أليسكيرين.&nbsp;</p></li></ul><p>&nbsp;</p><p>إذا كان أيٌّ مما سبق ينطبق عليك، يُرجى إبلاغ طبيبك أو الصيدلي قبل تناول تونيستا.&nbsp;</p><p>&nbsp;</p><p>تحذيرات واحتياطات&nbsp;</p><p>&nbsp; تحدَّث إلى طبيبك قبل تناول تونيستا إذا كنت تعاني أو قد عانيت من قبل من أيٍّ من الحالات أو الأمراض التَّالية:&nbsp;</p><ul><li><p>مرض كلوي أو جراحة زرع كلية.&nbsp;</p></li></ul><ul><li><p>تضييق الأوعية الدَّموية إلى إحدى أو كلا الكليتين (ضيق بالشريان الكلوي).&nbsp;</p></li></ul><ul><li><p>مرض كبدي.&nbsp;</p></li></ul><ul><li><p>مشاكل قلبية.&nbsp;</p></li></ul><ul><li><p>ارتفاع في مستويات هرمون الألدوستيرون (مما يؤدي الى احتباس المياه والملح في الجسم مع اختلال توازن المعادن المختلفة في الدَّم).&nbsp;</p></li></ul><ul><li><p>يُحتمل حدوث انخفاض ضغط الدَّم (هبوط ضغط الدَّم)، إذا كنت تعاني من الجفاف (فقدان الجسم المفرط للمياه) أو تعاني من نقص الأملاح بسبب العلاج المدر للبول (&#39;أقراص الماء&#39;)، النظام الغذائي منخفض الملح، الإسهال أو القيء.&nbsp;</p></li></ul><ul><li><p>ارتفاع مستويات البوتاسيوم بالدَّم.&nbsp;</p></li></ul><ul><li><p>مرض السُّكَّرِي.&nbsp;</p></li></ul><ul><li><p>تضيُّق الشريان الأورطي (تضيُّق الأبهر).&nbsp;</p></li></ul><ul><li><p>ألم بالصدر مرتبط بالقلب عند الرَّاحة أو مع بذل أقل مجهود (ذبحة صدرية غير مستقرة).&nbsp;</p></li></ul><ul><li><p>نوبة قلبية خلال الأربعة أسابيع الأخيرة.&nbsp;</p></li></ul><p>&nbsp;</p><p>تحدَّث إلى طبيبك قبل تناوُل تونيستا:&nbsp;</p><ul><li><p>إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:&nbsp;</p></li></ul><ul><li><p>&nbsp;مثبط الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ (على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل)، لا سيما إذا كنت مُصابًا بمرض السُّكَّرِي المرتبط بمشاكل الكُلى.&nbsp;</p></li></ul><ul><li><p>&nbsp;أليسكيرين.&nbsp;</p></li></ul><p>قد يُجري لك طبيبك فحصًا لوظائف الكُلى وضغط الدَّم وكمية الإليكتروليتات (على سبيل المثال: البوتاسيوم) في دمك على فترات منتظمة. انظر أيضًا&nbsp; &quot;لا تتناول تونيستا في الحالات الآتية&quot;.&nbsp;</p><ul><li><p>إذا كنت من المرضى من كبار السن وتستلزم حالتك زيادة جرعتك.&nbsp;</p></li></ul><p>&nbsp;</p><p>تحدث إلى طبيبك إذا أُصبت بألم في البطن أو غثيان أو قيء أو إسهال بعد تناول عقار ميكارديس بلس. سيحدد طبيبك ما ستتلقاه من علاجٍ بعدها. لا تتوقف عن تناول عقار تونيستا من تلقاء نفسك.&nbsp;</p><p>&nbsp;</p><p>في حالة الخضوع للجراحة أو التخدير، يجب أن تخبر طبيبك بأنك تتناول تونيستا.&nbsp;</p><p>&nbsp;</p><p>الأطفال والمراهقون&nbsp;</p><p>لا ينصح باستخدام تونيستا في الأطفال والمراهقين حتى سن 18 عامًا.&nbsp;</p><p>&nbsp;</p><p>تناوُل تونيستا مع أدوية أخرى&nbsp;</p><p>يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول، أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.&nbsp;</p><p>قد يكون طبيبك بحاجة إلى تغيير جرعة تلك الأدوية الأخرى أو اتخاذ احتياطات أخرى. وفي بعض الحالات، قد تكون مضطرًّا للتَّوقف عن تناول أحد الأدوية. ينطبق ذلك بشكل خاص على الأدوية المذكورة أدناه:&nbsp;</p><ul><li><p>الأدوية المحتوية على الليثيوم والمستخدمة لعلاج بعض أنواع الاكتئاب.&nbsp;</p></li></ul><ul><li><p>الأدوية التي قد تزيد من مستويات البوتاسيوم بالدَّم مثل بدائل الملح المحتوية على البوتاسيوم، ومدرات البول المُوفرة للبوتاسيوم (بعض &quot;أقراص الماء&quot;).&nbsp;</p></li></ul><ul><li><p>حاصرات مستقبلات أنجيوتنسين-2.&nbsp;</p></li></ul><ul><li><p>مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ أو أليسكيرين (انظر أيضًا المعلومات الواردة تحت العناوين &quot;لا تتناول تونيستا في الحالات الآتية&quot; و&quot;تحذيرات واحتياطات&quot;).&nbsp;</p></li></ul><ul><li><p>مضادات الالتهاب غير الستيرويدية (على سبيل المثال: حمض أسيتيل الساليسيليك أو الإيبوبروفين)، والهيبارين، ومثبطات المناعة (على سبيل المثال: سيكلوسبورين أو تاكروليموس)، والمضاد الحيوي ترايميثوبريم.&nbsp;</p></li></ul><ul><li><p>ريفامبيسين، إريثروميسين، كلاريثروميسين (مضادات حيوية).&nbsp;&nbsp;</p></li></ul><ul><li><p>نبتة سانت جونز.&nbsp;</p></li></ul><ul><li><p>دانتُرولِين (تسريب لعلاج اضطرابات درجة حرارة الجسم الشديدة).&nbsp;</p></li></ul><ul><li><p>الأدوية التي تُستَخدَم لتغيير طريقة عمل جهازك المناعي (على سبيل المثال: سيروليموس وتيمسيروليموس&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وإفيروليموس).&nbsp;</p></li></ul><ul><li><p>الأدوية المستخدمة لعلاج فيروس نقص المناعة البشري/ الإيدز (على سبيل المثال: ريتونافير) أو لعلاج العدوى الفطرية (على سبيل المثال: كيتوكونازول).&nbsp;</p></li></ul><ul><li><p>ديلتِيازِيم (دواء للقلب).&nbsp;</p></li></ul><ul><li><p>سيمفاستاتين لعلاج مستويات الكوليسترول المرتفعة.&nbsp;</p></li></ul><ul><li><p>ديجوكسين.&nbsp;</p></li></ul><p>&nbsp;</p><p>كما هو الحال مع الأدوية الأخرى الخافضة لضغط الدَّم، قد يقل تأثير تونيستا عند تناوُلك لمضادات الالتهاب غير الستيرويدية (على سبيل المثال: حمض أسيتيل الساليسيليك أو الإيبوبروفين) أو الكورتيكوستيرويدات.&nbsp;</p><p>قد يرفع تونيستا من التَّأثير الخافض لضغط الدَّم للأدوية الأخرى التي تستخدم لعلاج ارتفاع ضغط الدَّم أو الأدوية التي يمكن أن تحدث انخفاضًا بضغط الدَّم (على سبيل المثال: باكلوفين، أميفوستين، مضادات الذهان أو مضادات الاكتئاب).&nbsp;</p><p>&nbsp;</p><p>تناوُل تونيستا مع الأغذية والمشروبات&nbsp;</p><p>يمكن أن يؤدي تناوُل الكحوليات إلى تفاقم الانخفاض بضغط الدَّم. قد تلاحظ هذا في شكل دوخة عند الوقوف.&nbsp;&nbsp;</p><p>&nbsp;</p><p>يجب تجنب تناوُل عصير الجريب فروت والجريب فروت عند تناوُل تونيستا. ذلك لأن الجريب فروت وعصير الجريب فروت قد يؤديان إلى ارتفاع مستويات المادة الفعَّالة أملوديبيـن في الدَّم لدى بعض المرضى وقد يُؤدي إلى زيادة تأثير تونيستا الخافض لضغط الدَّم.&nbsp;</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية&nbsp;</p><p>الحمل&nbsp;</p><p>يجب عليكِ إخبار طبيبك إذا كنتِ تعتقدين أنكِ قد تصبحين حاملًا أو تنوين الحمل. سينصحكِ طبيبكِ في العادة بالتوقف عن تناوُل تونيستا قبل أن تصبِحي حاملًا أَو بِمجرّد أَن تعلمي بأنكِ حاملٌ، وسينصحك بِتناوُل دواء آخر بدلًا من تونيستا. لا ينصح باستخدام تونيستا في وقت مبكر من الحمل، ويجب ألا يتم تناوُله إذا تعدى حملكِ الشهر الثالث، حيث إنه قد يسبب أضرار خطيرة لطفلكِ إذا تم استخدامه بعد الشهر الثالث من الحمل.&nbsp;</p><p>&nbsp;</p><p>الرضاعة الطبيعية&nbsp;</p><p>لقد ثبت أن أملوديبين ينتقل إلى حليب الثدي بكميات قليلة.&nbsp;</p><p>أخبري طبيبكِ إذا كنتِ تُرضعين طفلكِ طبيعيًّا، أو على وشك البدء في إرضاعه طبيعيًّا. لا ينصح باستخدام تونيستا من قبل الأمهات المرضعات، وقد يختار لكِ طبيبكِ علاجًا آخر إذا كنتِ ترغبين في الإرضاع، خاصة إذا كان طفلكِ حديث الولادة، أو مبتسرًا.&nbsp;</p><p>&nbsp;</p><p>استشيري طبيبكِ أو الصيدلي قبل تناوُل أي دواء.&nbsp;</p><p>&nbsp;</p><p>القيادة واستخدام الآلات&nbsp;</p><p>قد يواجه بعض الأشخاص آثارًا جانبيةً مثل الإغماء ، النعاس ، الدوخة أو شعور بالدوران (دوار) عند علاجهم من ارتفاع ضغط الدَّم. إذا واجهت هذه الآثار الجانبية، فلا تمارس القيادة أو تستخدم الآلات.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>يحتوي تونيستا على السوربيتول.&nbsp;</p><p>يحتوي هذا الدَّواء على 337.28 مجم سوربيتول بكل قرص.&nbsp;</p><p>&nbsp;</p><p>يُعد السوربيتول مصدرًا للفركتوز. إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات أو إذا تم تشخيص إصابتك بعَدَم تَحَمُّلِ الفَرَكْتوز الوراثي (HFI)، وهو اضطراب جيني نادر لا يستطيع جسم الشَّخص المصاب به تكسير الفركتوز، فتحدَّث إلى طبيبك قبل تناول هذا الدَّواء أو تلقيه.&nbsp;</p><p>&nbsp;</p><p>يحتوي تونيستا على الصوديوم&nbsp;</p><p>يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل قرص، أي يُمكِننا القول أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا من كيفية التَّناول.&nbsp;</p><p>&nbsp;</p><p>الجرعة المعتادة هي قرص واحد يوميًّا. حاول أن تتناول القرص في نفس الوقت من كل يوم.&nbsp;&nbsp;</p><p>أخرج قرص تونيستا من الشريط فقط قبل تناوُله مباشرة.&nbsp;</p><p>&nbsp;</p><p>يمكنكِ تناوُل تونيستا مع الطعام أو بدونه. يجب بلع الأقراص مع قليل من الماء أو أحد المشروبات غير الكحولية الأخرى.&nbsp;</p><p>&nbsp;</p><p>إذا لم يكن كبدك يعمل بشكل سليم، فيجب ألا تتجاوز الجرعة المعتادة قرصًا واحدًا 40 مجم/ 5 مجم أو قرصًا واحدًا 40 مجم/ 10 مجم في اليوم.&nbsp;</p><p>&nbsp;</p><p>إذا تناولت كمية أكثر مما يجب من تونيستا&nbsp;</p><p>إذا تناولت كمية كبيرة من الأقراص بطريق الخطأ، فاتصل فورًا بالطبيب أو الصيدلي، أو قسم الطوارئ بأقرب مستشفى إليك. قد تشعر بانخفاض ضغط الدَّم وتسارُع ضربات القلب. تم الإبلاغ أيضًا عن بطء ضربات القلب، دوخة، قصور وظائف الكُلى بما في ذلك الفشل الكُلوي، انخفاض ضغط الدَّم الملحوظ والمستمر لفترة طويلة بما في ذلك الصدمة والوفاة.&nbsp;</p><p>&nbsp;</p><p>&nbsp; قد تتراكم سوائل زائدة في رئتيك (وذمة رئوية)؛ ما يسبب ضيقًا في التنفس قد يحدث بعد فترة تصل إلى 24-48 ساعة من تناوُله.&nbsp;</p><p>&nbsp;</p><p>إذا أغفلت تناوُل تونيستا&nbsp;</p><p>إذا أغفلت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها ثم استمر كما كنت من قبل. إذا لم تتناول جرعتك اليومية في أحد الأيام، فتناول جرعتك المعتادة في اليوم التَّالي. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.&nbsp;</p><p>&nbsp;</p><p>إذا توقفت عن تناوُل تونيستا&nbsp;</p><p>من المهم تناوُلك لتونيستا يوميًّا حتى يخبرك طبيبك بخلاف ذلك. إذا كان لديك انطباع بأن تأثير تونيستا قويٌّ جدًّا أو ضعيفٌ جدًّا، فتحدَّث إلى طبيبك أو الصيدلي.&nbsp;</p><p>&nbsp;</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.&nbsp;</p><p>&nbsp;</p><p>بعض الآثار الجانبية قد تكون خطيرة وتحتاج إلى عناية طبية فورية:&nbsp;</p><p>&nbsp;</p><p>يجب عليك زيارة طبيبك على الفور إذا تعرضت لأيٍّ من الأعراض التَّالية:&nbsp;</p><p>&nbsp;</p><p>تعفن الدَّم (غالبا ما يُعرف بـ &quot;تسمم الدَّم&quot;، وهو عدوى شديدة في الجسم بالكامل وتكون مصحوبة بحمى شديدة وإحساس بتوعك شديد)، تورم سريع للجلد والغشاء المخاطي (وذمة وعائية)، هذه الآثار الجانبية نادرة (قد تُؤثر في ما يصل إلى 1 من كل 1000 شخص) ولكنها خطيرة للغاية وعلى المرضى التَّوقف عن تناوُل الدَّواء ومراجعة الطبيب على الفور. إذا لم يتم علاج تلك الآثار الجانبية، فقد تكون مميتة. لُوحظ زيادة حدوث تعفُّن الدَّم مع تلميسارتان بمفرده، مع ذلك لا يُمكِن استبعاد حدوثه مع تونيستا.&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية الشائعة (قد تُؤثر في ما يصل إلى 1 من بين كل 10 أشخاص)&nbsp;</p><p>دوخة، تورُّم الكاحل (وذمة).&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية غير الشائعة (قد تُؤثر في ما يصل إلى 1 من كل 100 شخص)&nbsp;</p><p>نعاس، صداع نصفي، صداع، وخز أو تنميل باليدين أو القدمين، شعور بالدوران (دوار)، بطء ضربات القلب، خَفَقان (الإحساس بضربات القلب)، انخفاض ضغط الدَّم، دوخة عند الوقوف (انخفاض ضغط الدَّم الانتصابي)، احمرار الجلد، سُعال، أوجاع بالمعدة (ألم بالبطن)، إسهال، شعور بالإعياء (الغثيان)، حكة، ألم بالمفاصل، تقلصات عضلية، ألم بالعضلات، عدم القدرة على الحصول على الانتصاب، ضعف، ألم بالصدر، تعب، تورُّم (وذمة)، ارتفاع مستويات إنزيمات الكبد.&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية النَّادرة (قد تؤثر في ما يصل إلى 1 من كل 1000 شخص)&nbsp;</p><p>عدوى المسالك البولية، شعور بالحزن (اكتئاب)، شعور بالقلق، عدم القدرة على النوم (أرق)، إغماء، تلف عصبي في اليدين أو القدمين، انخفاض حاسة اللمس، اضطرابات التذوُّق، ارتجاف، قيء، تضخُّم اللثة، شعور غير مريح بالبطن، جفاف الفم، أكزيما (اضطراب بالجلد)، احمرار بالجلد، طفح جلدي، ألم بالظهر، ألم بالساق، الرَّغبة في التبوُّل أثناء الليل، شعور بالتوعُّك (شعور بالضيق)، ارتفاع مستويات حمض اليوريك في الدَّم.&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية النَّادرة جدًّا (قد تُؤثر في ما يصل إلى 1 من كل 10000 شخص)&nbsp;</p><p>تندُّب مُترقٍّ في نسيج الرئة (مرض الرئة الخلالي [بشكل رئيسي الالتهاب الرئوي الخلالي والالتهاب الرئوي ذو الحمضات الزائدة])&nbsp;</p><p>&nbsp;</p><p>لُوحظ حدوث الآثار الجانبية التَّالية مع المكونات تلميسارتان أو أملوديبين، وقد تحدث أيضًا مع تونيستا:&nbsp;</p><p>&nbsp;</p><p>تلميسارتان&nbsp;</p><p>تم الإبلاغ عن الآثار الجانبية الإضافية التَّالية في المرضى الذين يتناولون تلميسارتان بمفرده:&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية غير الشائعة (قد تُؤثر في ما يصل إلى 1 من كل 100 شخص)&nbsp;</p><p>عدوى المسالك البولية، عدوى الجهاز التنفسي العلوي (على سبيل المثال: التهاب الحلق، التهاب الجيوب الأنفية، نزلات البرد)، نقص خلايا الدَّم الحمراء (فقر الدَّم)، ارتفاع مستويات البوتاسيوم بالدَّم، ضيق التنفس، انتفاخ، زيادة التعرُّق، تلف بالكُلى يشمل عجز الكُلى المفاجئ عن العمل، ارتفاع مستويات الكرياتينين.&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية النادرة (قد تؤثر في ما يصل إلى 1 من كل 1000 شخص)&nbsp;</p><p>زيادة بعض خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات)، انخفاض عدد الصفائح الدَّموية (نقص الصفائح الدَّموية)، تفاعلات حساسية (على سبيل المثال: طفح جلدي، حكة، صعوبة التنفس، أزيز بالصدر، تورُّم الوجه أو انخفاض ضغط الدَّم)، انخفاض مستويات السكر بالدَّم (في مرضى السُّكَّرِي)، قصور بالرؤية، تسارع ضربات القلب، تهيُّج المعدة، اختلال وظائف الكبد، شرى (أرتكاريا)، طفح دوائي، التهاب الأوتار، مرض شبيه بالأنفلونزا (على سبيل المثال: ألم عضلي، شعور عام بالتوعُّك)، انخفاض الهيموجلوبين (أحد بروتينات الدَّم)، ارتفاع مستويات فُسفوكيناز الكرياتينين في الدَّم، انخفاض مستويات الصوديوم.&nbsp;</p><p>&nbsp;&nbsp;</p><p>حدثت معظم حالات اختلال وظائف الكبد والاضطرابات الكبدية من خبرة مرحلة ما بعد تسويق تلميسارتان في المرضى اليابانيين. يُعد المرضى اليابانيون أكثر عرضة للإصابة بهذا الأثر الجانبي.&nbsp;</p><p>&nbsp;</p><p>غير معروفة&nbsp;</p><p>وذمة وعائية معوية: تم الإبلاغ عن حدوث تورم في الأمعاء تظهر معه أعراض مثل ألم بالبطن وغثيان وقيء وإسهال بعد استخدام منتجات مماثلة.&nbsp;</p><p>&nbsp;</p><p>أملوديبين&nbsp;</p><p>تم الإبلاغ عن الآثار الجانبية الإضافية التَّالية في المرضى الذين يتناولون أملوديبين بمفرده:&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية الشائعة (قد تُؤثر في ما يصل إلى 1 من كل 10 شخص)&nbsp;</p><p>عادات الأمعاء المتغيرة، الإسهال، الإمساك، الاضطرابات البصرية، الرؤية المزدوجة، وتورم الكاحل.&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية غير الشائعة (قد تُؤثر في ما يصل إلى 1 من كل 100 شخص)&nbsp;</p><p>تغيُّرات في المزاج، قصور بالرؤية، طنين بالأذنين، ضيق بالتَّنفس، عطس/سيلان الأنف ، تساقط الشعر، كدمات ونزيف غير مُعتاد (تلف خلايا الدَّم الحمراء)، تغيُّر لون الجلد، زيادة التعرُّق، صعوبة التبوُّل، زيادة الحاجة إلى التبوُّل خاصة في الليل، تضخُّم الثدي لدى الرجال، ألم، زيادة الوزن، انخفاض الوزن.&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية النادرة (قد تؤثر في ما يصل إلى 1 من كل 1000 شخص)&nbsp;&nbsp;</p><p>ارتباك.&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية النادرة جدًّا (قد تؤثر في ما يصل إلى 1 من كل 10000 شخص)&nbsp;</p><p>انخفاض عدد خلايا الدَّم البيضاء (نقص كريات الدَّم البيضاء)، انخفاض عدد الصفائح الدَّموية (نقص الصفائح الدَّموية)، تفاعلات حساسية (على سبيل المثال: طفح جلدي، حكة، صعوبة التنفس، أزيز بالصدر، تورُّم الوجه أو انخفاض ضغط الدَّم)، ارتفاع نسبة السكر بالدَّم، انتفاض عضلي لا يُمكِن التحكم به أو حركات نفضية، نوبة قلبية، عدم انتظام ضربات القلب، التهاب الأوعية الدَّموية، التهاب البنكرياس، التهاب بطانة المعدة (التهاب المعدة)، التهاب الكبد، اصفرار الجلد (يرقان)، ارتفاع مستويات الإنزيمات الكبدية مصحوب بيرقان، تسارع تورُّم الجلد والغشاء المخاطي (وذمة وعائية)، تفاعلات جلدية شديدة، شرى (أرتكاريا)، تفاعلات حساسية شديدة مع طفح في صورة بثور على الجلد والأغشية المخاطية (التهاب الجلد التقشري، متلازمة ستيفنز جونسون)، زيادة حساسية الجلد لأشعة الشمس، زيادة التوتر العضلي.&nbsp;</p><p>&nbsp;</p><p>غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)&nbsp;</p><p>تفاعلات الحساسية الشديدة مع حالات طفح جلدي مصحوب ببثور بالجلد والأغشية المخاطية (انحلال البشرة النخري التَّسَمُّمِيّ).&nbsp;</p><p>الإبلاغ عن الآثار الجانبية&nbsp;&nbsp;</p><p>إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك. بما في ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.&nbsp;&nbsp;</p><p>من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ&nbsp;هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.&nbsp;</p><p>&nbsp;</p><p>لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.&nbsp;</p><p>&nbsp;</p><p>يُحفَظ في درجة حرارة أقل من 30 درجة مئوية، ويخزن داخل العبوة الأصلية للحماية من الضوء والرطوبة.&nbsp;</p><p>أخرج قرص تونيستا من الشريط فقط قبل تناوُله مباشرة.&nbsp;</p><p>&nbsp;</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتويات تونيستا&nbsp;</p><p>&nbsp;</p><p>- المواد الفعَّالة هي تلميسارتان وأملوديبين.&nbsp;</p><p>&nbsp;</p><p>تونيستا 80 مجم/ 5 مجم: يحتوي كل قرص على 80 مجم تلميسارتان و 5 مجم أملوديبين (في هيئة بيسيلات الأملوديبين).&nbsp;</p><p>&nbsp;</p><p>تونيستا 80 مجم/ 10 مجم: يحتوي كل قرص على 80 مجم تلميسارتان 10 مجم أملوديبين (في هيئة بيسيلات الأملوديبين).&nbsp;</p><p>&nbsp;</p><p>- المكونات الأخرى هي سيليكا غروية لا مائية، إف سي إف أزرق لامع (133E)، أكسيد الحديديك الأسود (172E)، أكسيد الحديديك الأصفر (172E)، ستيرات الماغنسيوم، نشا الذرة، ميجلومين، سليلوز دقيق التَّبلور، بوفيدون &quot;25K&quot;، نشا سابق التجلتن مُعَد من نشا الذرة، هيدروكسيد الصوديوم (انظر قسم 2)، سوربيتول (420E) (انظر قسم 2).&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل تونيستا ومحتويات العبوة</strong></p><p>&nbsp;</p><p>تونيستا 80 مجم/ 5 مجم أقراص عبارة عن أقراص باللونين الأزرق والأبيض، بيضاوية الشكل، من طبقتين، يبلغ طولها حوالي 16 ملم محفور على الجانب الأبيض رمز المُنتَج A3 وشعار الشركة.&nbsp;</p><p>&nbsp;</p><p>تونيستا 80 مجم/ 10 مجم أقراص عبارة عن أقراص باللونين الأزرق والأبيض، بيضاوية الشكل، من طبقتين، يبلغ طولها حوالي 16 ملم محفور على الجانب الأبيض رمز المُنتَج A4 وشعار الشركة.&nbsp;</p><p>&nbsp;</p><p>يتوافر تونيستا في عبوة مطوية تحتوي على 14 (2 &times; 7)، 28 (4 &times; 7)، 56 (8 &times; 7)، 98 (14 &times; 7) قرصًا في شرائط من الألومنيوم/ الألومنيوم، أو عبوات تحتوي على 30، 90، 360 (4 &times; 90) قرصًا في أشرطة من الألومنيوم/ الأولومنيوم مثقوبة لجرعة مفردة.&nbsp;</p><p>قد لا تكون جمیع التركیزات و أحجام العبوات مسجلة أو مسوقة ببلدك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق </strong></p><p dir="RTL">شركة بوهرينجر إنجيلهايم إنترناشونال المحدودة</p><p dir="RTL">173شارع بنجر</p><p dir="RTL">&nbsp;55216إنجلهايم أيه إم راين</p><p dir="RTL">ألمانيا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p dir="RTL">شركة سيبلا المحدودة</p><p dir="RTL">رقم القطعة: L-139 إلى L-146،<br />منطقة فيرنا الصناعية</p><p dir="RTL">فيرنا جوا،</p><p dir="RTL">الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسيمبر 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Twynsta 80 mg/10 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 80 mg telmisartan and 10 mg amlodipine (as amlodipine besilate). 

 

Excipient(s) with known effect:  

Each tablet contains 337.28 mg sorbitol (E420). 

 

For the full list of excipients, see section 6.1. 

 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet 

 

Blue and white oval shaped two layer tablets of approximately 16 mm length engraved with the product code A4 and the company logo on the white layer. 

 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults:&nbsp;</p><p>&nbsp;</p><p>Add on therapy&nbsp;</p><p>Twynsta 80 mg/10 mg is indicated in adults whose blood pressure is not adequately controlled on Twynsta 40 mg/10 mg or Twynsta 80 mg/5 mg.&nbsp;</p><p>&nbsp;</p><p>Replacement therapy&nbsp;</p><p>Adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology&nbsp;</p><p>The recommended dose of this medicinal product is one tablet per day.&nbsp;</p><p>&nbsp;</p><p>The maximum recommended dose is one tablet 80 mg telmisartan/10 mg amlodipine per day. This medicinal product is indicated for long term treatment.&nbsp;</p><p>&nbsp;</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects (see section 4.5).&nbsp;</p><p>&nbsp;</p><p>Add on therapy&nbsp;</p><p>Twynsta 80 mg/10 mg may be administered in patients whose blood pressure is not adequately controlled on Twynsta 40 mg/10 mg or Twynsta 80 mg/5 mg.&nbsp;</p><p>&nbsp;</p><p>Individual dose titration with the components (i.e. amlodipine and telmisartan) is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed combination may be considered.&nbsp;</p><p>&nbsp;</p><p>Patients treated with 10 mg amlodipine who experience any dose limiting adverse reactions such as oedema, may be switched to Twynsta 40 mg/5 mg once daily, reducing the dose of amlodipine without reducing the overall expected antihypertensive response.&nbsp;</p><p>&nbsp;</p><p>Replacement therapy&nbsp;</p><p>Patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses in one tablet once daily. .&nbsp;</p><p>&nbsp;</p><p>Elderly (&gt; 65 years)&nbsp;</p><p>No dose adjustment is necessary for elderly patients. Little information is available in the very elderly patients.&nbsp;</p><p>Normal amlodipine dose regimens are recommended in the elderly, but increase of dose should take place with care (see section 4.4).&nbsp;</p><p>&nbsp;</p><p>Renal impairment&nbsp;&nbsp;</p><p>Limited experience is available in patients with severe renal impairment or haemodialysis. Caution is advised when using telmisartan/amlodipine in such patients as amlodipine is not dialysable and telmisartan is not removed from blood by hemofiltration and not dialysable (see also section 4.4).&nbsp;</p><p>No posology adjustment is required for patients with mild to moderate renal impairment.&nbsp;</p><p>&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>Twynsta is contraindicated in patients with severe hepatic impairment (see section 4.3).&nbsp;</p><p>In patients with mild to moderate hepatic impairment telmisartan/amlodipine should be administered with caution. For telmisartan the posology should not exceed 40 mg once daily (see section 4.4).&nbsp;&nbsp;</p><p>&nbsp;</p><p>Paediatric population&nbsp;</p><p>The safety and efficacy of telmisartan/amlodipine in children aged below 18 years have not been established. No data are available.&nbsp;</p><p>&nbsp;</p><p>Method of administration&nbsp;</p><p>Oral use.&nbsp;</p><p>Twynsta can be taken with or without food. It is recommended to take Twynsta with some liquid.&nbsp;</p><p>Twynsta should be kept in the sealed blister due to the hygroscopic property of the tablets. Tablets&nbsp;&nbsp;</p><p>should be taken out of the blister shortly before administration (see section 6.6).&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to dihydropyridine derivatives, or to any of the excipients listed in section 6.1 

Second and third trimesters of pregnancy (see sections 4.4 and 4.6) 

Biliary obstructive disorders and severe hepatic impairment 

Shock (including cardiogenic shock) 

Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis)  

Haemodynamically unstable heart failure after acute myocardial infarction 

 

The concomitant use of telmisartan/amlodipine with aliskiren-containing medicinal products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5, and 5.1). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>Angiotensin II receptor blockers should not be initiated during pregnancy. Unless continued angiotensin II receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor blockers should be stopped immediately, and, if appropriate, alternative therapy should be started (see section 4.3 and 4.6).&nbsp;</p><p>&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>Telmisartan is mostly eliminated in the bile. Patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance.&nbsp;&nbsp;</p><p>The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dose recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose.&nbsp;&nbsp;</p><p>Telmisartan/amlodipine should therefore be used with caution in these patients.&nbsp;</p><p>&nbsp;</p><p>Renovascular hypertension&nbsp;</p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system (RAAS).&nbsp;&nbsp;</p><p>&nbsp;</p><p>Renal impairment and kidney transplantation&nbsp;</p><p>When telmisartan/amlodipine is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of telmisartan/amlodipine in patients with a recent kidney transplant. Amlodipine is not dialysable and telmisartan is not removed from blood by hemofiltration and not dialysable.&nbsp;</p><p>&nbsp;</p><p>Volume and/or sodium depleted patients&nbsp;</p><p>Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by e.g. vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of telmisartan. If hypotension occurs with telmisartan/amlodipine, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.&nbsp;</p><p>&nbsp;</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)&nbsp;</p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).&nbsp;</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.&nbsp;</p><p>&nbsp;</p><p>Other conditions with stimulation of the renin-angiotensin-aldosterone system&nbsp;</p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8).&nbsp;</p><p>&nbsp;</p><p>Primary aldosteronism&nbsp;</p><p>Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of telmisartan is not recommended.&nbsp;</p><p>&nbsp;</p><p>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy&nbsp;</p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.&nbsp;</p><p>&nbsp;</p><p>Unstable angina pectoris, acute myocardial infarction&nbsp;</p><p>There are no data to support the use of telmisartan/amlodipine in unstable angina pectoris and during or within one month of a myocardial infarction.&nbsp;</p><p>&nbsp;</p><p>Patients with cardiac failure&nbsp;</p><p>In an amlodipine long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group (see section 5.1). Therefore, patients with heart failure should be treated with caution.&nbsp;</p><p>Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.&nbsp;</p><p>&nbsp;</p><p>Diabetic patients treated with insulin or antidiabetics&nbsp;</p><p>In these patients hypoglycaemia may occur under telmisartan treatment. Therefore, in these patients an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated.&nbsp;</p><p>&nbsp;</p><p>Hyperkalaemia&nbsp;</p><p>The use of medicinal products that affect the reninangiotensinaldosterone system may cause hyperkalaemia. Hyperkalaemia may be fatal in the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events,.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Before considering the concomitant use of medicinal products that affect the reninangiotensinaldosterone system, the benefit risk ratio should be evaluated.&nbsp;</p><p>The main risk factors for hyperkalaemia to be considered are:&nbsp;</p><p>- Diabetes mellitus, renal impairment, age (&gt;70 years)&nbsp;</p><p>- Combination with one or more other medicinal products that affect the reninangiotensinaldosterone system and/or potassium supplements. Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor blockers, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.&nbsp;</p><p>- Intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extensive trauma).&nbsp;</p><p>&nbsp;</p><p>Serum potassium should be monitored closely in these patients (see section 4.5).&nbsp;</p><p>&nbsp;</p><p>Elderly patients&nbsp;</p><p>The increase of the amlodipine dose should take place with care in the elderly patients (see section 4.2 and 5.2).&nbsp;</p><p>&nbsp;</p><p>Sorbitol&nbsp;</p><p>This medicinal product contains 337.28 mg sorbitol in each tablet.&nbsp;&nbsp;</p><p>Sorbitol is a source of fructose. Twynsta is not recommended for use in patients with hereditary fructose intolerance (HFI).&nbsp;</p><p>&nbsp;</p><p>Sodium&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.&nbsp;</p><p>&nbsp;</p><p>Ischaemic heart disease&nbsp;</p><p>As with any antihypertensive medicinal product, excessive reduction of blood pressure in patients with ischaemic cardiomyopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.&nbsp;</p><p>&nbsp;</p><p>Intestinal angioedema&nbsp;</p><p>Intestinal angioedema has been reported in patients treated with angiotensin II receptor antagonists (see section 4.8). These patients presented with abdominal pain, nausea, vomiting and diarrhoea. Symptoms resolved after discontinuation of angiotensin II receptor antagonists. If intestinal angioedema is diagnosed, telmisartan should be discontinued and appropriate monitoring should be initiated until complete resolution of symptoms has occurred.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions between the two components of this fixed dose combinations have been observed in clinical studies.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Interactions linked to the combination&nbsp;</p><p>No drug interaction studies have been performed.&nbsp;</p><p>&nbsp;</p><p>To be taken into account with concomitant use&nbsp;&nbsp;</p><p>&nbsp;</p><p>Other antihypertensive medicinal products&nbsp;&nbsp;</p><p>The blood pressure lowering effect of telmisartan/amlodipine can be increased by concomitant use of other antihypertensive medicinal products.&nbsp;</p><p>&nbsp;</p><p>Medicinal products with blood pressure lowering potential&nbsp;</p><p>Based on their pharmacological properties it can be expected that the following medicinal products may potentiate the hypotensive effects of all antihypertensives including this medicinal product, e.g. baclofen, amifostine, neuroleptics or antidepressants. Furthermore, orthostatic hypotension may be aggravated by alcohol.&nbsp;</p><p>&nbsp;</p><p>Corticosteroids (systemic route)&nbsp;</p><p>Reduction of the antihypertensive effect.&nbsp;</p><p>&nbsp;</p><p>Interactions linked to telmisartan&nbsp;&nbsp;</p><p>&nbsp;</p><p>Concomitant use not recommended&nbsp;</p><p>&nbsp;</p><p>Potassium sparing diuretics or potassium supplements&nbsp;</p><p>Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss. Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium. If concomitant use is indicated because of documented hypokalaemia, they should be used with caution and with frequent monitoring of serum potassium.&nbsp;</p><p>&nbsp;</p><p>Lithium&nbsp;</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor blockers, including telmisartan. If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Other antihypertensive agents acting on the renin-angiotensin-aldosterone system (RAAS)&nbsp;</p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).&nbsp;</p><p>&nbsp;</p><p>Concomitant use requiring caution&nbsp;</p><p>&nbsp;</p><p>Non-steroidal anti-inflammatory medicinal products&nbsp;</p><p>NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dose regimens, COX2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor blockers.&nbsp;</p><p>In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the coadministration of angiotensin II receptor blockers and medicinal products that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.&nbsp;</p><p>&nbsp;</p><p>Ramipril&nbsp;</p><p>In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC0-24 and Cmax of ramipril and ramiprilat. The clinical relevance of this observation is not known.&nbsp;</p><p>&nbsp;</p><p>Concomitant use to be taken into account&nbsp;</p><p>&nbsp;</p><p>Digoxin&nbsp;</p><p>When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49 %) and in trough concentration (20 %) were observed. When initiating, adjusting, and discontinuing telmisartan, monitor digoxin levels in order to maintain levels within the therapeutic range.&nbsp;</p><p>&nbsp;</p><p>Interactions linked to amlodipine&nbsp;</p><p>&nbsp;</p><p>Concomitant use requiring caution&nbsp;</p><p>&nbsp;</p><p>CYP3A4 inhibitors&nbsp;</p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure resulting in an increased risk of hypotension. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.&nbsp;</p><p>&nbsp;</p><p>CYP3A4 inducers&nbsp;</p><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine&nbsp;</p><p>may vary. Therefore, blood pressure should be monitored and dose regulation considered both&nbsp;</p><p>during and after concomitant medication particularly with strong CYP3A4 inducers (e.g.&nbsp;</p><p>rifampicin, hypericum perforatum).&nbsp;</p><p>&nbsp;</p><p>Dantrolene (infusion)&nbsp;</p><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the coadministration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.&nbsp;</p><p>&nbsp;</p><p>Grapefruit and grapefruit juice&nbsp;</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended since bioavailability may be increased in certain patients resulting in increased blood pressure lowering effects.&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>Concomitant use to be taken into account&nbsp;</p><p>&nbsp;</p><p>Tacrolimus&nbsp;</p><p>There is a risk of increased tacrolimus blood levels when co-administered with amlodipine but the pharmacokinetic mechanism of this interaction is not fully understood. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.&nbsp;</p><p>&nbsp;</p><p>Cyclosporine&nbsp;</p><p>No drug interaction studies have been conducted with cyclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of cyclosporine were observed. Consideration should be given for monitoring cyclosporine levels in renal transplant patients on amlodipine, and cyclosporine dose reductions should be made as necessary.&nbsp;</p><p>&nbsp;</p><p>Mechanistic Target of Rapamycin (mTOR) Inhibitors&nbsp;</p><p>mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors.&nbsp;</p><p>&nbsp;</p><p>Simvastatin&nbsp;</p><p>Co-administration of multiple doses of 10 mg of amlodipine with simvastatin 80 mg resulted in an increase in exposure to simvastatin up to 77 % compared to simvastatin alone. Therefore, the dose of simvastatin in patients on amlodipine should be limited to 20 mg daily.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>There are limited data from the use of telmisartan/amlodipine in pregnant women. Animal reproductive toxicity studies with telmisartan/amlodipine have not been performed.&nbsp;</p><p>&nbsp;</p><p>Telmisartan&nbsp;</p><p>&nbsp;</p><p>The use of angiotensin II receptor blockers is not recommended during the first trimester of pregnancy (see section 4.4). The use of angiotensin II receptor blockers is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).&nbsp;</p><p>&nbsp;</p><p>Studies with telmisartan in animals have shown reproductive toxicity (see section 5.3).&nbsp;&nbsp;</p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor blockers, similar risks may exist for this class of medicinal products. Unless continued angiotensin II receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor blockers should be stopped immediately, and, if appropriate, alternative therapy should be started.&nbsp;</p><p>&nbsp;</p><p>Exposure to angiotensin II receptor blocker therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).&nbsp;</p><p>Should exposure to angiotensin II receptor blockers have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.&nbsp;</p><p>Infants whose mothers have taken angiotensin II receptor blockers should be closely observed for hypotension (see sections 4.3 and 4.4).&nbsp;</p><p>&nbsp;</p><p>Amlodipine&nbsp;</p><p>&nbsp;</p><p>The safety of amlodipine in human pregnancy has not been established.&nbsp;</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).&nbsp;</p><p>&nbsp;</p><p>Breastfeeding&nbsp;</p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3 &ndash; 7%, with a maximum of 15%. The effect of amlodipine on infants is unknown.&nbsp;</p><p>Because no information is available regarding the use of telmisartan during breast-feeding, telmisartan/amlodipine is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while breastfeeding a newborn or preterm infant.&nbsp;</p><p>&nbsp;</p><p>Fertility&nbsp;</p><p>No data from controlled clinical studies with the fixed dose combination or with the individual components are available.&nbsp;</p><p>&nbsp;</p><p>Separate reproductive toxicity studies with the combination of telmisartan and amlodipine have not been conducted.&nbsp;</p><p>In preclinical studies, no effects of telmisartan on male and female fertility were observed.&nbsp;</p><p>In some patients treated by calcium channel blockers, reversible biochemical changes in the head of spermatozoa have been reported. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Twynsta has moderate influence on the ability to drive and use machines. When driving vehicles or operating machinery it should be taken into account that syncope, somnolence, dizziness, or vertigo may occasionally occur when taking antihypertensive therapy (see section 4.8). If patients experience these adverse reactions, they should avoid potentially hazardous tasks such as driving or using machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>&nbsp;</p><p>The most common adverse reactions include dizziness and peripheral oedema. Serious syncope may occur rarely (less than 1 case per 1,000 patients).&nbsp;</p><p>&nbsp;</p><p>Adverse reactions previously reported with one of the individual components (telmisartan or amlodipine) may be potential adverse reactions with Twynsta as well, even if not observed in clinical trials or during the post-marketing period.&nbsp;</p><p>&nbsp;</p><p>Tabulated list of adverse reactions&nbsp;</p><p>The safety and tolerability of Twynsta has been evaluated in five controlled clinical studies with over 3,500 patients, over 2,500 of whom received telmisartan in combination with amlodipine.&nbsp;</p><p>&nbsp;</p><p>Adverse reactions have been ranked under headings of frequency using the following convention:&nbsp;</p><p>very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).&nbsp;&nbsp;</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.&nbsp;</p><p>&nbsp;</p><table border="1"><tbody><tr><td><p>System Organ&nbsp;</p><p>Class&nbsp;</p></td><td colspan="2"><p>Twynsta&nbsp;</p></td><td colspan="2"><p>Telmisartan&nbsp;</p></td><td><p>Amlodipine&nbsp;</p></td></tr><tr><td colspan="6"><p>Infections and infestations&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>upper respiratory tract infection including pharyngitis and&nbsp;</p><p>sinusitis, urinary tract infection including cystitis&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>cystitis&nbsp;</p></td><td><p>sepsis including fatal outcome1&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Blood and lymphatic system disorders:&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>anaemia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>thrombocytopenia, eosinophilia&nbsp;&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>leukocytopenia, thrombocytopenia&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Immune system disorders:&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>hypersensitivity, anaphylactic reaction&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>hypersensitivity&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Metabolism and nutrition disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>hyperkalaemia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>hypoglycaemia (in diabetic patients), hyponatraemia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>hyperglycaemia&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Psychiatric disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>mood change&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>depression,&nbsp;</p><p>anxiety,&nbsp;</p><p>insomnia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>confusion&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Nervous system disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Common&nbsp;</p></td><td colspan="2"><p>dizziness&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>somnolence,&nbsp;</p><p>migraine,&nbsp;</p><p>headache,&nbsp;</p><p>paraesthesia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>syncope,&nbsp;</p><p>peripheral neuropathy,&nbsp;</p><p>hypoaesthesia,&nbsp;</p><p>dysgeusia,&nbsp;</p><p>tremor&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>extrapyramidal syndrome,&nbsp;</p><p>hypertonia&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Eye disorders&nbsp;&nbsp;</p></td></tr><tr><td colspan="2"><p>Common&nbsp;</p><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>visual disturbance (including diplopia)&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>visual impairment&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>visual disturbance&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Ear and labyrinth disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>vertigo&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>tinnitus&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Cardiac disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>bradycardia,&nbsp;</p><p>palpitations&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>tachycardia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>myocardial infarction, arrhythmia,&nbsp;&nbsp;</p><p>ventricular tachycardia, atrial fibrillation&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Vascular disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>hypotension,&nbsp;</p><p>orthostatic&nbsp;</p><p>hypotension, flushing&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>vasculitis&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Respiratory, thoracic and mediastinal disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p><p>&nbsp;</p></td><td colspan="2"><p>cough&nbsp;</p><p>&nbsp;</p></td><td><p>dyspnoea&nbsp;</p></td><td><p>dyspnoea, rhinitis&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>interstitial lung disease3&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Gastrointestinal disorder&nbsp;</p></td></tr><tr><td colspan="2"><p>Common&nbsp;</p><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>altered bowel habits (including diarrhoea and constipation)&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>abdominal pain,&nbsp;</p><p>diarrhoea,&nbsp;</p><p>nausea&nbsp;</p><p>&nbsp;</p></td><td><p>flatulence&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>vomiting,&nbsp;</p><p>gingival hypertrophy,&nbsp;</p><p>dyspepsia,&nbsp;</p><p>dry mouth&nbsp;</p><p>&nbsp;</p></td><td><p>stomach discomfort&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>pancreatitis, gastritis&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Hepato-biliary disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>hepatic function abnormal, liver disorder2&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>hepatitis, jaundice,&nbsp;&nbsp;</p><p>hepatic enzyme elevations (mostly consistent with cholestasis)&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Skin and subcutaneous tissue disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>pruritus&nbsp;</p></td><td><p>hyperhidrosis&nbsp;</p></td><td><p>alopecia, purpura, skin discolouration, hyperhidrosis&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>eczema, erythema,&nbsp;</p><p>rash&nbsp;</p></td><td><p>angioedema (including fatal outcome),&nbsp;&nbsp;</p><p>drug eruption,&nbsp;&nbsp;</p><p>toxic skin eruption, urticaria&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Very rare&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>angioedema,&nbsp;&nbsp;</p><p>erythema multiforme, urticaria,&nbsp;&nbsp;</p><p>exfoliative dermatitis, Stevens-Johnson syndrome,&nbsp;&nbsp;</p><p>photosensitivity&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Not known&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>toxic epidermal necrolysis&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Musculoskeletal and connective tissue disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Common&nbsp;</p><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>ankle swelling&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>arthralgia,&nbsp;</p><p>muscle spasms&nbsp;</p><p>(cramps in legs),&nbsp;</p><p>myalgia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>back pain,&nbsp;</p><p>pain in extremity (leg&nbsp;</p><p>pain)&nbsp;</p><p>&nbsp;</p></td><td><p>tendon pain (tendinitis like symptoms)&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Renal and urinary disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>renal impairment&nbsp;&nbsp;</p><p>including acute renal failure&nbsp;</p><p>&nbsp;</p></td><td><p>micturition disorder, pollakiuria&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td colspan="2"><p>nocturia&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Reproductive system and breast disorders&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td colspan="2"><p>erectile dysfunction&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>gynaecomastia&nbsp;</p></td></tr><tr><td colspan="6"><p>General disorders and administration site condition&nbsp;</p></td></tr><tr><td colspan="2"><p>Common&nbsp;</p></td><td><p>peripheral oedema&nbsp;</p><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Uncommon&nbsp;</p></td><td><p>asthenia,&nbsp;</p><p>chest pain, fatigue,&nbsp;</p><p>oedema&nbsp;</p><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td><p>pain&nbsp;</p></td></tr><tr><td colspan="2"><p>Rare&nbsp;</p></td><td><p>malaise&nbsp;</p></td><td colspan="2"><p>influenza-like illness&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>Investigations&nbsp;</p></td></tr><tr><td><p>Uncommon&nbsp;</p></td><td colspan="3"><p>hepatic enzymes&nbsp;</p><p>increased&nbsp;</p></td><td><p>blood creatinine&nbsp;&nbsp;</p><p>increased&nbsp;</p><p>&nbsp;</p></td><td><p>weight increased,&nbsp;&nbsp;</p><p>weight decreased&nbsp;</p></td></tr><tr><td><p>Rare&nbsp;</p></td><td colspan="3"><p>blood uric acid&nbsp;</p><p>increased&nbsp;</p></td><td><p>blood creatine phosphokinase increased, haemoglobin decreased&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>1: the event may be a chance finding or related to a mechanism currently not known&nbsp;</p><p>2: most cases of hepatic function abnormal / liver disorder from post-marketing experience with telmisartan occurred in Japanese patients. Japanese patients are more likely to experience these adverse reactions.&nbsp;</p><p>3: cases of interstitial lung disease (predominantly interstitial pneumonia and eosinophilic pneumonia) have been reported from post-marketing experience with telmisartan&nbsp;</p><p>&nbsp;</p><p>Description of selected adverse reactions&nbsp;</p><p>&nbsp;</p><p>Intestinal angioedema&nbsp;</p><p>Cases of intestinal angioedema have been reported after the use of angiotensin II receptor antagonists (see section 4.4).&nbsp;</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions&nbsp;&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms&nbsp;</p><p>Signs and symptoms of overdose are expected to be in line with exaggerated pharmacological effects. The most prominent manifestations of telmisartan overdose are expected to be hypotension and tachycardia; bradycardia, dizziness, increase in serum creatinine, and acute renal failure have also been reported.&nbsp;</p><p>Overdose with amlodipine may result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.&nbsp;</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48 hours post-ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.&nbsp;</p><p>&nbsp;</p><p>Treatment&nbsp;</p><p>The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends on the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and / or gastric lavage. Activated charcoal may be useful in the treatment of overdose of both telmisartan and amlodipine.&nbsp;&nbsp;</p><p>Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position with elevation of extremities, with salt and volume replacement given quickly. Supportive treatment should be instituted.&nbsp;&nbsp;</p><p>Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine. Amlodipine is not dialysable and telmisartan is not removed from blood by hemofiltration and not dialysable.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II receptor blockers (ARBs) and calcium channel blockers, ATC code: C09DB04.&nbsp;</p><p>&nbsp;</p><p>Twynsta combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor blocker, telmisartan, and a dihydropyridinic calcium channel blocker, amlodipine.&nbsp;</p><p>The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.&nbsp;</p><p>Twynsta once daily produces effective and consistent reductions in blood pressure across the 24hour therapeutic dose range.&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>Telmisartan&nbsp;</p><p>Telmisartan is an orally active and specific angiotensin II receptor (type AT1) blocker. Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. Telmisartan does not exhibit any partial agonist activity at the AT1 receptor. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting. Telmisartan does not show affinity for other receptors, including AT2 and other less characterised AT receptors. The functional role of these receptors is not known, nor is the effect of their possible overstimulation by angiotensin II, whose levels are increased by telmisartan. Plasma aldosterone levels are decreased by telmisartan. Telmisartan does not inhibit human plasma renin or block ion channels. Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin. Therefore it is not expected to potentiate bradykinin-mediated adverse reactions.&nbsp;</p><p>&nbsp;</p><p>In humans, an 80 mg dose of telmisartan almost completely inhibits the angiotensin II evoked blood pressure increase. The inhibitory effect is maintained over 24 hours and still measurable up to 48 hours.&nbsp;</p><p>&nbsp;</p><p>After the first dose of telmisartan, the antihypertensive activity gradually becomes evident within 3 hours. The maximum reduction in blood pressure is generally attained 4 to 8 weeks after the start of treatment and is sustained during long-term therapy.&nbsp;</p><p>&nbsp;</p><p>The antihypertensive effect persists constantly over 24 hours after dosing and includes the last 4 hours before the next dose as shown by ambulatory blood pressure measurements. This is confirmed by trough to peak ratios consistently above 80 % seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies. There is an apparent trend to a dose relationship to a time to recovery of baseline systolic blood pressure. In this respect data concerning diastolic blood pressure are inconsistent.&nbsp;&nbsp;</p><p>&nbsp;</p><p>In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate. The contribution of the medicinal product&rsquo;s diuretic and natriuretic effect to its hypotensive activity has still to be defined. The antihypertensive efficacy of telmisartan is comparable to that of substances representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril).&nbsp;</p><p>&nbsp;</p><p>Upon abrupt cessation of treatment with telmisartan, blood pressure gradually returns to pre-treatment values over a period of several days without evidence of rebound hypertension.&nbsp;&nbsp;</p><p>&nbsp;</p><p>The incidence of dry cough was significantly lower in patients treated with telmisartan than in those given angiotensin converting enzyme inhibitors in clinical trials directly comparing the two antihypertensive treatments.&nbsp;</p><p>&nbsp;</p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.&nbsp;</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHROND was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.&nbsp;</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.&nbsp;</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.&nbsp;</p><p>&nbsp;</p><p>Amlodipine&nbsp;</p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, leading to reductions in peripheral vascular resistance and in blood pressure. Experimental data indicate that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. Amlodipine is relatively vessel-selective, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells.&nbsp;</p><p>&nbsp;</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.&nbsp;</p><p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.&nbsp;</p><p>&nbsp;</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.&nbsp;</p><p>&nbsp;</p><p>Use in patients with heart failure&nbsp;</p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class IIIV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.&nbsp;</p><p>&nbsp;</p><p>A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.&nbsp;</p><p>&nbsp;</p><p>In a follow-up, long term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema.&nbsp;</p><p>&nbsp;</p><p>Telmisartan/Amlodipine&nbsp;</p><p>In an 8week multicenter, randomised, double-blind, placebocontrolled, parallel group factorial study in 1461 patients with mild to severe hypertension (mean seated diastolic blood pressure &ge;95 and &le;119 mmHg), treatment with each combination dose of Twynsta resulted in significantly greater diastolic and systolic blood pressure reductions and higher control rates compared to the respective monotherapy components.&nbsp;</p><p>&nbsp;</p><p>Twynsta showed dose-related reductions in systolic/diastolic blood pressure across the therapeutic dose range of -21.8/-16.5 mmHg (40 mg/5 mg), -22.1/-18.2 mmHg (80 mg/5 mg), -24.7/-20.2 mmHg (40 mg/10 mg) and -26.4/-20.1 mmHg (80 mg/10 mg). The reduction in diastolic blood pressure &lt;90 mmHg was achieved in 71.6 %, 74.8 %, 82.1 %, 85.3 % of patients respectively. Values are adjusted for baseline and country.&nbsp;</p><p>&nbsp;</p><p>The majority of the antihypertensive effect was attained within 2 weeks after initiation of therapy.&nbsp;</p><p>In a subset of 1050 patients with moderate to severe hypertension (DBP &ge;100 mmHg) 32.7 &ndash; 51.8 % responded sufficiently to monotherapy of either telmisartan or amlodipine. The observed mean changes in systolic/diastolic blood pressure with a combination therapy containing amlodipine 5 mg (-22.2/-17.2 mmHg with 40 mg/5 mg; -22.5/-19.1 mmHg with 80 mg/5 mg) were comparable to or greater than those seen with amlodipine 10 mg (-21.0/-17.6 mmHg) and associated with significant lower oedema rates (1.4 % with 40 mg/5 mg; 0.5 % with 80 mg/5 mg; 17.6 % with amlodipine 10 mg).&nbsp;</p><p>&nbsp;</p><p>Automated ambulatory blood pressure monitoring (ABPM) performed in a subset of 562 patients confirmed the results seen with in-clinic systolic and diastolic blood pressure reductions consistently over the entire 24hours dosing period.&nbsp;</p><p>&nbsp;</p><p>In a further multicentre, randomised, double-blind, active-controlled, parallel group study, a total of 1097 patients with mild to severe hypertension who were not adequately controlled on amlodipine 5 mg received Twynsta (40 mg/5 mg or 80 mg/5 mg) or amlodipine alone (5 mg or 10 mg). After 8 weeks of treatment, each of the combinations was statistically significantly superior to both amlodipine monotherapy doses in reducing systolic and diastolic blood pressures (-13.6/-9.4 mmHg, -15.0/-10.6 mmHg with 40 mg/5 mg, 80 mg/5 mg versus -6.2/-5.7 mmHg, -11.1/-8.0 mmHg with amlodipine 5 mg and 10 mg and higher diastolic blood pressure control rates compared to the respective monotherapies were achieved (56.7 %, 63.8 % with 40 mg/5 mg and 80 mg/5 mg versus 42 %, 56.7 % with amlodipine 5 mg and 10 mg). Oedema rates were significantly lower with 40 mg/5 mg and 80 mg/5 mg compared to amlodipine 10 mg (4.4 % versus 24.9 %, respectively).&nbsp;</p><p>&nbsp;</p><p>In another multicentre, randomised, double-blind, active-controlled, parallel group study, a total of 947 patients with mild to severe hypertension who were not adequately controlled on amlodipine 10 mg received Twynsta (40 mg/10 mg or 80 mg/10 mg) or amlodipine alone (10 mg). After 8 weeks of treatment, each of the combination treatments was statistically significantly superior to amlodipine monotherapy in reducing diastolic and systolic blood pressure (-11.1/-9.2 mmHg, -11.3/ -9.3 mmHg with 40 mg/10 mg, 80 mg/10 mg versus -7.4/-6.5 mmHg with amlodipine 10 mg) and higher diastolic blood pressure normalisation rates compared to monotherapy were achieved (63.7 %, 66.5 % with 40 mg/10 mg, 80 mg/10 mg versus 51.1 % with amlodipine 10 mg).&nbsp;</p><p>&nbsp;</p><p>In two corresponding open-label long-term follow up studies performed over a further 6 months the effect of Twynsta was maintained over the trial period. Furthermore it was shown that some patients not adequately controlled with Twynsta 40 mg/10 mg had additional blood pressure reduction by up-titration to Twynsta 80 mg/10 mg.&nbsp;</p><p>&nbsp;</p><p>The overall incidence of adverse reactions with Twynsta in the clinical trial programme was low with only 12.7 % of patients on treatment experiencing adverse reactions. The most common adverse reactions were peripheral oedema and dizziness, see also section 4.8. The adverse reactions reported were in agreement with those anticipated from the safety profiles of the components telmisartan and amlodipine. No new or more severe adverse reactions were observed. The oedema related events (peripheral oedema, generalised oedema, and oedema) were consistently lower in patients who received Twynsta as compared to patients who received amlodipine 10 mg. In the factorial design trial the oedema rates were 1.3 % with Twynsta 40 mg/5 mg and 80 mg/5 mg, 8.8 % with Twynsta 40 mg/10 mg and 80 mg/10 mg and 18.4 % with Amlodipine 10 mg. In patients not controlled on amlodipine 5 mg the oedema rates were 4.4 % for 40 mg/5 mg and 80 mg/5 mg and 24.9 % for amlodipine 10 mg.&nbsp;</p><p>&nbsp;</p><p>The antihypertensive effect of Twynsta was similar irrespective of age and gender, and was similar in patients with and without diabetes.&nbsp;</p><p>&nbsp;</p><p>Twynsta has not been studied in any patient population other than hypertension. Telmisartan has been studied in a large outcome study in 25,620 patients with high cardiovascular risk (ONTARGET). Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and angiographically documented coronary artery disease.&nbsp;</p><p>&nbsp;</p><p>Paediatric population&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Twynsta in all subsets of the paediatric population in hypertension (see section 4.2 for information on paediatric use).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic of the fixed dose combination&nbsp;&nbsp;</p><p>The rate and extent of absorption of Twynsta are equivalent to the bioavailability of telmisartan and amlodipine when administered as individual tablets.&nbsp;</p><p>&nbsp;</p><p>Absorption&nbsp;</p><p>Absorption of telmisartan is rapid although the amount absorbed varies. The mean absolute bioavailability for telmisartan is about 50 %. When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC0-&infin;) of telmisartan varies from approximately 6 % (40 mg dose) to approximately 19 % (160 mg dose). By 3 hours after administration, plasma concentrations are similar whether telmisartan is taken fasting or with food.&nbsp;&nbsp;</p><p>&nbsp;</p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 612 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80 %. Amlodipine bioavailability is not affected by food ingestion.&nbsp;</p><p>&nbsp;</p><p>Distribution&nbsp;</p><p>Telmisartan is largely bound to plasma protein (&gt;99.5 %), mainly albumin and alpha-1 acid glycoprotein. The mean steady state apparent volume of distribution (Vdss) is approximately 500 l.&nbsp;</p><p>&nbsp;</p><p>The volume of distribution of amlodipine is approximately 21 l/kg. In vitro studies have shown that approximately 97.5 % of circulating amlodipine is bound to plasma proteins in hypertensive patients.&nbsp;</p><p>&nbsp;</p><p>Biotransformation&nbsp;</p><p>Telmisartan is metabolised by conjugation to the glucuronide of the parent compound. No pharmacological activity has been shown for the conjugate.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Amlodipine is extensively (approximatively 90 %) metabolised by the liver to inactive metabolites.&nbsp;</p><p>&nbsp;</p><p>Elimination&nbsp;</p><p>Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination halflife of &gt;20 hours. The maximum plasma concentration (Cmax) and, to a smaller extent, the area under the plasma concentration-time curve (AUC), increase disproportionately with dose. There is no evidence of clinically relevant accumulation of telmisartan taken at the recommended dose. Plasma concentrations were higher in females than in males, without relevant influence on efficacy.&nbsp;</p><p>&nbsp;</p><p>After oral (and intravenous) administration, telmisartan is nearly exclusively excreted with the faeces, mainly as unchanged compound. Cumulative urinary excretion is &lt;1 % of dose. Total plasma clearance (Cltot) is high (approximately 1,000 ml/min) compared with hepatic blood flow (about 1,500 ml/min).&nbsp;</p><p>&nbsp;</p><p>Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours consistent with once daily dosing. Steady-state plasma levels are reached after continuous administration for 7&ndash;8 days. Ten per cent of original amlodipine and 60 % of amlodipine metabolites are excreted in urine.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Linearity/non-linearity&nbsp;&nbsp;</p><p>The small reduction in AUC for telmisartan is not expected to cause a reduction in the therapeutic efficacy. There is no linear relationship between doses and plasma levels. Cmax and to a lesser extent AUC increase disproportionately at doses above 40 mg.&nbsp;</p><p>&nbsp;</p><p>Amlodipine exhibits linear pharmacokinetics.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Paediatric population (age below 18 years)&nbsp;</p><p>No pharmacokinetic data are available in the paediatric population.&nbsp;</p><p>&nbsp;</p><p>Gender&nbsp;</p><p>Differences in plasma concentrations of telmisartan were observed, with Cmax and AUC being approximately 3 and 2fold higher, respectively, in females compared to males.&nbsp;</p><p>&nbsp;</p><p>Elderly&nbsp;</p><p>The pharmacokinetics of telmisartan do not differ in young and elderly patients.&nbsp;</p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. In elderly patients, amlodipine clearance tends to decline with resulting increases in AUC and elimination half-life.&nbsp;</p><p>&nbsp;</p><p>Renal impairment&nbsp;</p><p>In patients with mild to moderate and severe renal impairment, doubling of plasma concentrations of telmisartan was observed. However, lower plasma concentrations were observed in patients with renal insufficiency undergoing dialysis. Telmisartan is highly bound to plasma protein in renal-insufficient subjects and cannot be removed by dialysis. The elimination half-life is not changed in patients with renal impairment. The pharmacokinetics of amlodipine are not significantly influenced by renal impairment.&nbsp;</p><p>&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability of telmisartan up to nearly 100 %. The elimination half-life of telmisartan is not changed in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 4060 % in AUC.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since the non-clinical toxicity profiles of telmisartan and amlodipine are not overlapping, no exacerbation of toxicity was expected for the combination. This has been confirmed in a subchronic (13week) toxicology study in rats, in which dose levels of 3.2/0.8, 10/2.5 and 40/10 mg/kg of telmisartan and amlodipine were tested.&nbsp;</p><p>&nbsp;</p><p>Preclinical data available for the components of this fixed dose combination are reported below.&nbsp;</p><p>&nbsp;</p><p>Telmisartan&nbsp;</p><p>In preclinical safety studies, doses producing exposure comparable to that in the clinical therapeutic range caused reduced red cell parameters (erythrocytes, haemoglobin, haematocrit), changes in renal haemodynamics (increased blood urea nitrogen and creatinine), as well as increased serum potassium in normotensive animals. In dogs, renal tubular dilation and atrophy were observed. Gastric mucosal injury (erosion, ulcers or inflammation) also was noted in rats and dogs. These pharmacologically-mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, were prevented by oral saline supplementation. In both species, increased plasma renin activity and hypertrophy/hyperplasia of the renal juxtaglomerular cells were observed. These changes, also a class effect of angiotensin converting enzyme inhibitors and other angiotensin II receptor blockers, do not appear to have clinical significance.&nbsp;</p><p>No clear evidence of a teratogenic effect was observed, however at toxic dose levels of telmisartan an effect on the postnatal development of the offsprings such as lower body weight and delayed eye opening was observed.&nbsp;</p><p>There was no evidence of mutagenicity and relevant clastogenic activity in in vitro studies and no evidence of carcinogenicity in rats and mice.&nbsp;</p><p>&nbsp;</p><p>Amlodipine&nbsp;</p><p>&nbsp;</p><p>Reproductive toxicology&nbsp;</p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at doses approximately 50 times greater than the maximum recommended dose for humans based on mg/kg.&nbsp;</p><p>&nbsp;</p><p>Impairment of fertility&nbsp;</p><p>There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses of up to 10 mg amlodipine/kg/day (about 8 times* the maximum recommended human dose of 10 mg/day on an mg/m2 basis).&nbsp;&nbsp;</p><p>In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.&nbsp;</p><p>&nbsp;</p><p>Carcinogenesis, mutagenesis&nbsp;</p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dose levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.&nbsp;</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.&nbsp;</p><p>&nbsp;</p><p>*Based on patient weight of 50 kg&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colloidal anhydrous silica&nbsp;</p><p>Brilliant blue FCF (E133)&nbsp;</p><p>Ferric oxide black (E172)&nbsp;</p><p>Ferric oxide yellow (E172)&nbsp;</p><p>Magnesium stearate&nbsp;</p><p>Maize starch&nbsp;</p><p>Meglumine&nbsp;</p><p>Microcrystalline cellulose&nbsp;</p><p>Povidone K25&nbsp;</p><p>Pregelatinised starch (prepared from maize starch)&nbsp;</p><p>Sodium hydroxide&nbsp;</p><p>Sorbitol (E420)&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.&nbsp; Store in the original package in order to protect from light and moisture.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/aluminium blisters (PA/Al/PVC/Al) in a carton containing 14, 28, 56, 98 tablets or aluminium/aluminium perforated unit dose blisters (PA/Al/PVC/Al) in a carton containing 30 x 1, 90 x 1 tablets and multipacks containing 360 (4 packs of 90 x 1) tablets.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Not all strengths and pack sizes are registered or marketed in your country.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Telmisartan should be kept in the sealed blister due to the hygroscopic property of the tablets. Tablets&nbsp;</p><p>should be taken out of the blister shortly before administration.&nbsp;&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boehringer Ingelheim International GmbH
Binger Str. 173
55216 Ingelheim am Rhein
Germany


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>